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OBJECTIVE The aim of this study was to report further experience with transcatheter closure of the patent
ductus arteriosus (PDA) using the Amplatzer duct occluder (ADO).
BACKGROUND The design of previously used devices is not ideal for this purpose, and their use has been
associated with several drawbacks, especially in large PDAs.
METHODS Forty-three patients, aged 0.3 to 33 years (mean 6.4 6 6.7 years), with a moderate to large,
type A to E PDA, underwent attempted transcatheter closure using the ADO. The device is
a plug-shaped repositionable occluder made of 0.004-in. nitinol wire mesh. It is delivered
through a 5F to 6F long sheath. The mean PDA diameter (at the pulmonary end) was 3.9 6
1.2 mm (range 2.2 to 8 mm). All patients had color flow echocardiographic follow-up (6 to
24 months) at 24 h, 1 and 3 months after closure, and at 6-month intervals thereafter.
RESULTS The mean ADO diameter was 6.1 6 1.4 mm (range 4 to 10 mm). Complete angiographic
closure was seen in 40 of 43 patients (93%; 95% confidence interval [CI] 85.4% to 100%). The
remaining three patients had a trivial angiographic shunt through the ADO. At 24 h, color
flow mapping revealed no shunt in all patients. A 9F long sheath was required for
repositioning of a misplaced 8-mm device into the pulmonary artery. The mean fluoroscopy
time was 7.9 6 1.6 min (range 4.6 to 12 min). There were no complications. No obstruction
of the descending aorta or the pulmonary artery branches was noted on Doppler follow-up
studies. Neither thromboembolization nor hemolysis or device failure was encountered.
CONCLUSIONS Transcatheter closure using the ADO is an effective and safe therapy for the majority of
patients with patency of the arterial duct. Further studies are required to establish long-term
results in a larger patient population. (J Am Coll Cardiol 2000;35:1016–21) © 2000 by the
American College of Cardiology
In 1967, Porstmann et al. (1) were the first to employ
successfully an Ivalon plug for transcatheter closure of a
patent ductus arteriosus (PDA). Since then, various occlud-
ing devices and coils have been used in numerous patients
with quite satisfactory results. In spite of obvious advantages
of the percutaneous techniques in infants and small children
with moderate and large PDAs, the percutaneous tech-
niques have significant limitations. Large delivery sheaths,
cumbersome implantation techniques, device embolizations
and a high rate of residual shunting are some of the
drawbacks of previously prescribed techniques (2–13). Re-
cently, Masura et al. (14) reported complete closure of
moderate-to-large sized PDAs in 23 of 24 patients using
the Amplatzer duct occluder (ADO), a new device manu-
factured by AGA Medical Corporation and experimentally
tested at the University of Minnesota. In this report, we
present further experience in 43 patients, with ductus
measuring up to 8.0 mm in diameter, who underwent
transcatheter closure with the ADO.
METHODS
Patient population. From May 1997 to February 1999, 43
patients (14 males and 29 females) with PDA underwent
attempted transcatheter closure using the ADO. The me-
dian age of the 43 patients was 6.6 years (range 0.3 to 33
years) and the median weight was 20.3 kg (range 4.2 to
77 kg). Ten patients had symptoms of heart failure and/or
failure to thrive. All patients had echocardiographic evi-
dence of significant left-to-right shunting through the PDA
with left atrial enlargement and ventricular volume overload.
Informed parental consent was obtained in each patient.
Patients with additional congenital cardiac anomalies that
would require cardiac surgery, body weight less than 4 kg,
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and PDA diameter smaller than 2 mm were excluded from
the study.
Device and delivery system. The ADO (AGA Medical
Corporation, Golden Valley, Minnesota) has been de-
scribed in detail in previous reports (14). In brief, this
occluder is a cone-shaped device 7 mm in length made of a
0.004-inch Nitinol wire mesh (Fig. 1). A 2-mm retention
skirt extends radially around the distal part of the device
assuring secure fixation in the mouth of the PDA. Prosthe-
ses are currently available in sizes ranging from 6-4 to
14-12 mm at increments of 2 mm. The larger measurement
is at the aortic side and the smaller diameter is at the
pulmonary end. The device is attached by a recessed
microscrew to a 0.038-in. delivery cable made of stainless
steel. It is delivered through a 5F to 6F long sheath. For
introduction into the delivery sheath, the device is pulled
into a special Teflon loader.
Procedure. The technique of transcatheter closure was
similar to that described by Masura et al. (14). After
percutaneous puncture of the femoral vein and artery, a
complete hemodynamic evaluation was performed with
pressure and saturation measurements taken in all cardiac
chambers. A biplane descending aortogram in anteriopos-
terior and lateral projection was performed with a 4F or 5F
pigtail catheter, which was introduced percutaneously, to
define the size and anatomy of the ductus. In four patients
(patients 2, 31, 37 and 42), it was difficult to measure the
diameter of the PDA by aortography. Therefore, “balloon
sizing” was performed from the venous side with a balloon-
tipped end-hole catheter (Arrow). Subsequently, a 4F or 5F
cobra type I (Cordis) catheter was advanced percutaneously
from the venous side through the PDA into the descending
aorta. Using an exchange 260-cm 0.035-in. guidewire, the
cobra catheter was exchanged for a 5F or 6F delivery sheath
that was advanced directly through the femoral vein and
positioned in the proximal aorta.
A proper size occluder (smaller diameter 1 to 3 mm larger
than the diameter of the pulmonary end of the ductus or
equal to the measured balloon “stretched” diameter) was
screwed to the delivery cable, compressed into the loader
and introduced into the guiding sheath. Under fluoroscopic
guidance, the ADO was advanced into the descending
aorta, where the retention disc was deployed. Once in
position, the disc was pulled gently against the orifice of the
PDA, which could be felt as a rhythmic tugging sensation in
synchrony with the cardiac cycle. Correct position was
confirmed by a hand injection of contrast medium through
the aortic catheter into the descending aorta. Using gentle
tension on the delivery cable, the sheath was pulled back to
deploy the conical part of the device into the ductus.
Two-dimensional color Doppler echocardiography and de-
scending aortography were performed after device place-
ment to document residual shunts, and left pulmonary
artery or aortic obstruction. Once optimal position was
confirmed, the ADO was released by counterclockwise
rotation of the delivery cable. A repeat aortogram was
performed to check for residual shunts. Prophylactic anti-
biotics were not administered during the procedure. All
patients were discharged 24 h after the procedure on no
medications. Endocarditis prophylaxis was discontinued at
the six-month follow-up visit if the ductus was completely
closed.
Follow-up. A chest radiograph and complete two-
dimensional and color Doppler echocardiographic studies
were performed on all patients at 24 h, 1 month and serially
at 3- to 6-month intervals. Special attention was paid to
residual ductal flow, left pulmonary artery or aortic stenosis
and wire fractures.
Statistical analysis. Results are expressed as mean value 6
SD, with confidence intervals given where applicable.
RESULTS
The clinical data and the outcome for the 43 patients are
shown in Table 1. According to the alphanumeric classifi-
cation proposed by Krichenko et al. (15), 32 patients had a
PDA type A, four had PDA type B, three had PDA type C,
two had PDA type D and two had PDA type E. Delivery of
the device was successful in all patients. The mean PDA
minimal (pulmonary end) diameter determined by aortog-
raphy was 3.9 6 1.2 mm (range 2.2 to 8 mm). The mean
ADO smallest diameter was 6.1 6 1.4 mm (range 4 to
10 mm). There was left-to-right shunting across the PDAs
in all patients, both by oxymetry and angiography. The
pulmonary/systemic flow ratio (Qp/Qs) varied between 1.5
and 4 (mean 2.4 6 0.7). Two patients (patients 36 and 41)
with significant pulmonary artery hypertension (mean pul-
Abbreviations and Acronyms
ADO 5 Amplatzer duct occluder
CI 5 confidence interval
PDA 5 patent ductus arteriosus
Q p/Q s 5 pulmonary/systemic flow ratio
Figure 1. Close-up view of the currently available ADO made of
0.004-in. Nitinol wire mesh. The arrow indicates the 2-mm
retention disc that assures secure position in the mount of the
PDA.
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monary artery pressure of 43 and 48 mm Hg, respectively)
showed immediate improvement with a reduction of the mean
pulmonary artery pressure to 22 and 28 mm, respectively.
In one patient (patient 37), during the deployment of the
conical part, an 8-mm device slipped into the pulmonary
artery. Several efforts to retract the device into the 6F
delivery sheath failed. The device being tilted by the blood
flow into an almost vertical position in relation to the sheath
made recapturing impossible. A 9F Amplatzer delivery
sheath had to be introduced, which allowed recapturing and
successful redeployment of the device. In one patient (pa-
tient 31), a small infant with a large tubular (type C) PDA,
deployment of the retention disc against the orifice of the
ductus caused severe aortic obstruction. Therefore, both the
retention disc and the conical part of the device were
deployed within the ductus (Fig. 2).
Table 1. Patient Characteristics and Outcome After Device Placement
No.
Age
(years)
Weight
(kg)
PDA Diameter
(mm)
PDA
Type
Device Size
(mm)
Results
Immed 1 day 1 month 3 month
1. 6 15 3.4 A 8-6 C C C C
2. 14 36 5.1 A 10-8 F C C C
3. 28 77 2.3 B 6-4 C C C C
4. 3.5 12 4.2 B 8-6 F C C C
5. 33 62 4 A 8-6 F C C C
6. 2.5 10.5 5.2 A 10-8 TL C C C
7. 1.5 10.5 2.5 C 6-4 C C C C
8. 2 17 3.6 A 8-6 C C C C
9. 9 20 3.5 B 8-6 F C C C
10. 3 12 3.6 A 8-6 F C C C
11. 3 18 3.7 A 8-6 TL C C C
12. 10 30 3.5 A 8-6 C C C C
13. 10 34 4 A 8-6 C C C C
14. 5 17 3.3 A 8-6 F C C C
15. 7 23 4 A 8-6 C C C C
16. 5.5 20 4 A 8-6 C C C C
17. 5.5 18 4.6 A 8-6 C C C C
18. 4 13 5 A 10-8 C C C C
19. 1.5 8 5 A 8-6 C C C C
20. 13 38 3.5 A 8-6 F C C C
21. 3 12 2.2 D 6-4 C C C C
22. 2.5 9 2.3 A 6-4 F C C C
23. 6 19 4 A 8-6 C C C C
24. 3 14 5 A 10-8 C C C C
25. 6 20 3.8 A 8-6 C C C C
26. 7 21 3.7 A 8-6 TL C C C
27. 7 30 6 A 10-8 C C C C
28. 8 21 3 C 6-4 C C C C
29. 16 47 5 A 10-8 C C C C
30. 9 26 4 A 8-6 C C C C
31. 0.3 4.2 5.2 C 8-6 C C C C
32. 0.6 5.5 2.4 A 6-4 C C C C
33. 0.6 6.8 2.3 A 6-4 C C C C
34. 1.5 8 3.8 A 8-6 C C C C
35. 1 8 3.2 A 8-6 C C C C
36. 4 14 5 E 10-8 C C C C
37. 2.5 9 6.2 A 10-8 F C C C
38. 3 15 2.3 A 6-4 F C C C
39. 6 17 5.4 A 10-8 C C C C
40. 2 12 2.2 D 6-4 C C C C
41. 2.5 11 3.4 E 8-6 C C C C
42. 6 28 8 A 12-10 C C C C
43. 9 33 3.5 B 8-6 C C C C
C 5 complete closure; F 5 foaming; Immed 5 immediately at the end of the procedure; PDA 5 patent ductus arteriosus; TL 5 trivial leak.
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Complete angiographic closure was present in 40 of 43
patients (93%; 95% confidence interval [CI] 85.4% to
100%) (Fig. 3). Foaming (trace angiographic residual shunt
and no contrast jet) was seen in 10 patients (28%) but
disappeared within 15 min. In three patients, there was a
trivial residual shunt immediately after the procedure. Flu-
oroscopy time was 7.9 6 1.6 min (range 4.6 to 18 min), and
total procedure time was 21.8 6 5.8 min (range 15 to
48 min). No complications were observed. All patients had
good distal lower extremity pulses. No patient required a
blood transfusion.
Follow-up. At 24 h, color Doppler flow mapping revealed
complete closure in all 43 patients (100%). No obstruction
of the left pulmonary artery or the descending aorta was noted.
Follow-up data were available in all 43 patients at one and
three months after the procedure. All patients had complete
closure with no evidence of device recanalization, migration,
wire fracture, thromboembolism, endocarditis or hemolysis.
DISCUSSION
Transcatheter closure of PDAs is an established technique
with no reported mortality and low morbidity. However,
treatment in infants and closure of large PDAs is still
associated with technical problems and a relatively high
incidence of residual shunting (2–13). Such residual shunts
have to be considered as failures because the patients remain
at risk of bacterial endocarditis.
In the present study, transcatheter closure with the ADO
was carried out in 43 patients with PDAs ranging from 2.2
to 8 mm at the smallest diameter. All PDAs were com-
pletely closed at 24 h with no complications during the
procedure or at short-term follow-up. It appears, therefore,
that the very high success rate and safety of the technique is
related to the simplicity of deployment and the novel design
of the device.
Comparison with the other devices. The ADO was
designed to improve the closure rate of moderate-to-large
sized PDAs regardless of anatomic configuration. Some
of the previously used devices are the Rashkind double
umbrella (C.R. Bard, Galway, Ireland) (2– 4), the Sideris
“buttoned” device (Custom Medical Devices, Amarillo,
Texas) (5,6), the Botallooccluder (7) and the Gianturco
spring coils (Cook Europe A/S, Bjaeverskov, Denmark)
(8 –13). Besides the coils, which can be delivered through
a 4F sheath, all other devices have to be delivered through
Figure 2. Steps of transcatheter closure technique using the ADO
in a 4-month-old, 4.2-kg infant (patient 31) with a large tubular
PDA. A, Descending aortogram in the lateral projection demon-
strating a large type C PDA measuring 5.2 mm in diameter. B,
Deployment of the retention disc (arrowhead) of a 6-mm ADO
against the orifice of the ductus results in severe aortic obstruction.
C, Repeat descending aortogram after deployment of the ADO
inside the PDA showing good position with no obstruction to the
aorta and foaming through the device. D, Descending aortogram
15 min after release of the device, revealing complete closure with
good device position.
Figure 3. Descending aortogram in the lateral projection obtained
from a patient (patient 36) with a large type E PDA, measuring
5 mm in diameter before (A) and after (B) implantation of an
8-mm ADO. Complete closure of the PDA has been achieved.
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a 7F to 11F sheath, which makes their application
difficult or impossible in infants and small children. The
ADO can be delivered through a 5F to 6F sheath, which
allows its use even in infancy. Moreover, in contrast to
other occluders, the ADO stents the PDA, forcing the
blood through a channel filled with highly thrombogenic
polyester material, which should result in a virtually 100%
occlusion rate by thrombosis. This obviates the need for
multiple device implantation and reduces the cost of the
procedure, the risk for embolization with tedious device
retrievals or other complications. The previously reported
incidence of residual shunting (3% to 38%) (2–13) is
much higher than in the present study (0%), including
those of Masura et al. (4%) (14). This excellent result in
our study was obtained by significantly oversizing the
devices more than recommended by the manufacturer
(2 mm). The only drawback is the possibility of signifi-
cant hemodynamic aortic obstruction by the retention
disc.
An important advantage of the ADO is that it can be
easily retracted into the delivery sheath and redeployed
several times. This does not only reduce the risk for surgical
or catheter removal of embolized devices but also reduces
the cost obviating the introduction of a new device. With
the exception of the detachable (controlled release) coils, all
other devices are not repositionable, and once deployed, it is
very laborious to reposition or to remove them. Misplace-
ment of the ADO across the PDA occurred in one of our
patients and was easily corrected by retracting the device
into a large sheath and redeploying it.
As compared with other devices, the ADO’s implantation
is much simpler without complicated mechanisms. This
significantly reduces the fluoroscopy time, and shortens the
learning curve for each operator. Indeed, the fluoroscopy
time in this study was much lower (7.9 min [range 4.6 to
18 min]) than reported for simple (10,12) (14.8 to 40 min
[range 4.2 to 152 min]) or detachable (13) (18.3 min [range
5 to 45 min]) spring coils, a technique that has recently
gained wide acceptance as the treatment of choice (11,13).
Device embolization. The most significant complication
of transcatheter closure of PDA has been reported to be
device embolization to the pulmonary artery (2–13), and
occasionally to the descending aorta (12). The previously
reported embolization rate ranged from 3% to 20% (2–13).
In the present study, the embolization rate was 0%. This is
most likely due to the simple delivery mechanism, the
design of ADO and the aforementioned oversizing of the
devices.
Limitation of the study. In contrast to the preliminary
work of Masura et al. (14), in this study, we successfully
closed PDAs up to 8 mm in diameter of all angiographic
types. However, the use of ADO, as well as the other
currently available occluders, cannot be recommended for
infants with moderate- to large-sized PDAs, in which
surgical closure remains the treatment of choice. This is due
to the fact that the device may protrude too much into the
descending aorta or the pulmonary artery, causing signifi-
cant obstruction. Because the PDA is a remnant of the sixth
aortic arch, it forms an about 30° angle with the aorta. The
retention disc of the ADO is at a right angle and, conse-
quently, it will extend partially into the aorta, particularly
with the B-type PDAs. In all the patients, this is not of
hemodynamic significance, but in babies, it may cause
partial aortic obstruction. A modification of the retention
disc is in process, which may eliminate this drawback of the
present device (Kurt Amplatz, personal communication).
Before the release of the device, aortic pressure measure-
ments should be carried out routinely. Protrusion into the
aorta with a significant gradient requires removal of the
device. However, protrusion into the left pulmonary artery
results mainly in a redistribution of blood flow with no
significant gradient. With growth of the child, the pulmo-
nary arteries enlarge considerably, and this type of partial
obstruction is expected to disappear at adolescence or long
before, without clinical consequences (16). Further clinical
testing is required to determine any potential limitations for
the use of the ADO in patients with small and especially
very small PDAs.
Conclusion. Our preliminary results prove that ADO is an
efficient and safe device for transcatheter closure of PDAs.
Further studies are required to establish long-term results in
a larger patient population.
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